CD23 Mouse, anti-Human, R718, Clone: EBVCS-5, BD OptiBuild™

Description

• The EBVCS-5 antibody specifically binds to human CD23, the low affinity receptor for human IgE (Fc epsilon RII or FcεRII), which is also known as C-type lectin domain family 4 member J (CLEC4J)
• CD23 is expressed as a ∼45 kDa type II membrane glycoprotein that is present at low density on most normal B lymphocytes and at higher levels on activated B lymphocytes, Epstein-Barr virus (EBV)-transformed lymphoblasts, chronic lymphocytic leukemia (CLL) cells of B-lymphocyte origin, and tonsillar B lymphocytes
• CD23 expression is induced on B cells by interleukin-4 (IL-4) and is lost after isotype switching to IgA, IgG, or IgE
• The CD23 antigen is not present on immature bone marrow B lymphocytes or on T lymphocytes
• CD23 may also be differentially expressed on monocytes, macrophages, eosinophils, platelets, dendritic cells, and Langerhans cells
• CD23 can mediate IgE-dependent cytotoxicity and phagocytosis by macrophages and eosinophils
• Soluble CD23 (sCD23) can be released by CD23-positive cells as a result of proteolytic cleavage of membrane CD23
• Larger fragments of sCD23 (eg, 25-37 kDa) retain their IgE-binding capacity whereas smaller fragments (ie, ≤ 12 kDa) do not
• Soluble CD23 may have immunoregulatory effects on the growth and differentiation of B cells and other cell types.